

DATA + PERSPECTIVES
**Clinical Investigators Explore the Current and Future
Management of HER2-Positive Breast Cancer**

Friday, December 13, 2019
7:30 PM – 9:00 PM
San Antonio, Texas

Moderator

Neil Love, MD

Faculty

Adam M Brufsky, MD, PhD
Lisa A Carey, MD

Sara Hurvitz, MD
Martine J Piccart-Gebhart, MD, PhD

Research
To Practice®

Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

Agenda

Module 1 – Dr Carey: *Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy*

Module 2 – Prof Piccart-Gebhart : *Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC*


Module 3 – Dr Brufsky: *Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC)*

Module 4 – Dr Hurvitz: *Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC*

The Second Annual Miami General Medical Oncology Symposium

**February 21-23, 2020
JW Marriott Miami Turnberry
Miami, Florida**

Dr. Bernard Fisher, Who Revolutionized Breast Cancer Treatment, Dies at 101



DATA + PERSPECTIVES
**Clinical Investigators Explore the Current and Future
Management of HER2-Positive Breast Cancer**

Friday, December 13, 2019
7:30 PM – 9:00 PM
San Antonio, Texas

Moderator

Neil Love, MD

Faculty


Adam M Brufsky, MD, PhD
Lisa A Carey, MD

Sara Hurvitz, MD
Martine J Piccart-Gebhart, MD, PhD

Research
To Practice®

HERRISK

A guide for patients based on a survey of breast cancer investigators



This booklet includes select graphics from an ongoing pilot evaluation of a new online tool developed by Research To Practice with project co-chairs Drs Sara Hurvitz and Hope Rugo.

HER RISK was conceived as a novel means to support therapeutic decision-making for patients with HER2-positive localized breast cancer by providing estimated numeric benefits of various adjuvant anti-HER2 therapies from 30 nationally recognized breast cancer investigators. Twenty-four common adjuvant scenarios were presented, and the researchers were asked to provide the estimates that they would provide to an interested patient on the baseline risk of relapse and how that changes with different HER2-targeted treatments.


If you would like to assist in the evaluation of this tool or provide informal feedback, please email us at Research@ResearchToPractice.com. Our grant provides limited funding to physicians and patients who assist in the evaluation.

Neil Love, MD
Editor

1 POSITIVE NODE (MICROSCOPIC)

HR-positive


HR-positive, HER2-positive, 1 positive node (microscopic)



Estimates provided to patients by 30 breast cancer clinical investigators

HR-positive


HR-positive, HER2-positive 1 positive node



Estimates provided to patients by 30 breast cancer clinical investigators

HR-negative


HR-negative, HER2-positive 1 positive node (microscopic)



Estimates provided to patients by 30 breast cancer clinical investigators

HR-negative

HR-negative, HER2-positive 1 positive node



Estimates provided to patients by 30 breast cancer clinical investigators

HR-positive, HER2-positive 2 positive nodes



-  70 people cancer free: no further treatment
-  15 people cancer free: chemotherapy/trastuzumab
-  2 more people cancer free by adding pertuzumab
-  2 more people cancer free by adding postadjuvant neratinib
-  11 people: cancer recurrence

